Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients

Gordon Chun‐Kau Chan, Win Hlaing Than, Bonnie Ching‐Ha Kwan, Ka‐Bik Lai, Ronald Chan, Jeremy Yuen‐Chun Teoh, Jack Kit‐Chung Ng, Kai‐Ming Chow, Winston Wing‐Shing Fung, Phyllis Mei‐Shan Cheng, Man-Ching Law, Chi‐Bon Leung, Philip Kam‐Tao Li, Cheuk‐Chun SzetoScientific 2022 · DOI

Abstract

Data regarding adipose and serum zinc alpha-2-glycoprotein (ZAG) expression and its association with body composition in patients with advanced chronic kidney disease (CKD) has historically been limited. This study aimed to quantify these expressions and evaluate their associations with longitudinal changes in body composition and mortality in incident dialysis patients. In a single-center prospective cohort study of 148 patients starting peritoneal dialysis, ZAG levels were measured in serum and fat tissue. Results indicated that both adipose and serum ZAG independently predicted adipose tissue mass (ATM). Over one year, adipose ZAG levels predicted changes in both ATM and lean tissue mass (LTM). Furthermore, serum ZAG levels were found to be a robust independent predictor of overall survival and infection-related mortality.

Introduction: Addressing the Obesity Paradox in CKD

Patients transitioning to dialysis for advanced chronic kidney disease (CKD) often face significant shifts in body composition. These changes typically manifest as "protein-energy wasting"—a loss of muscle mass—often accompanied by a paradoxical accumulation of fat. These alterations are not merely cosmetic; they are deeply linked to metabolic complications and increased mortality rates.

A significant hurdle in clinical management is the "obesity paradox." While obesity is a well-known risk factor for cardiovascular disease in the general population, it often appears to have a protective effect in dialysis patients. This phenomenon renders traditional metrics like Body Mass Index (BMI) unreliable for risk stratification. Consequently, there is an urgent need for biomarkers that can more accurately predict wasting and mortality. Zinc alpha-2-glycoprotein (ZAG), an adipokine known for its role in lipid mobilization, emerged as a potential candidate, though its specific role in the context of CKD remained poorly understood.

Methodology and Study Design

The researchers conducted a prospective cohort study at the Prince of Wales Hospital in Hong Kong, recruiting 148 incident peritoneal dialysis (PD) patients. The study employed a multi-modal assessment strategy:

  • ZAG Quantification: Adipose ZAG mRNA expression was measured via RT-QPCR from fat samples collected during PD catheter insertion. Serum ZAG levels were measured using ELISA four weeks post-dialysis initiation.
  • Body Composition Analysis: Multi-frequency bioimpedance spectroscopy (BCM) was used to quantify Lean Tissue Mass (LTM) and Adipose Tissue Mass (ATM) at baseline and at a one-year follow-up.
  • Clinical Follow-up: The primary endpoint was two-year all-cause mortality, with secondary outcomes focusing on longitudinal changes in body composition.
Flowchart of patient recruitment and clinical outcomes over a two-year follow-up period.

As shown in the flowchart, while 148 patients were initially recruited, follow-up body composition data was available for 117 patients at the one-year mark, providing a robust dataset for longitudinal analysis.

Key Findings: ZAG as a Predictor of Health Outcomes

Baseline and Longitudinal Body Composition

A primary finding of the study was the independent predictive value of both adipose and serum ZAG for baseline fat mass. Specifically, higher levels of ZAG expression were associated with lower adipose tissue mass at the start of the study.

Baseline correlation between adipose tissue mass (ATM) and adipose ZAG expression tertiles.

The longitudinal data revealed a significant trend: over the first year of dialysis, patients generally experienced an increase in fat mass (average ATM increase of 3.3 kg). Crucially, high adipose ZAG expression at baseline was a "red flag" for unfavorable shifts, significantly predicting both the gain in ATM and the loss of LTM. This suggests that ZAG may play a role in the degradation of muscle quality, possibly through fatty infiltration.

Survival and Mortality

Perhaps most significantly, serum ZAG levels proved to be a powerful predictor of survival. This association remained significant even after adjusting for confounding factors such as age, albumin levels, and baseline BMI. Lower serum ZAG levels were linked to a higher risk of all-cause mortality and infection-related death. This indicates that serum ZAG captures aspects of patient resilience and metabolic health that are not reflected in traditional physical measurements.

Discussion and Conclusion

The study highlights a notable "disconnect" between local (adipose) and systemic (serum) ZAG levels, suggesting that ZAG functions through both paracrine and endocrine pathways. While adipose ZAG is a superior predictor of physical wasting and fat accumulation, serum ZAG serves as a critical indicator of overall survival.

Despite limitations such as the single-center design and the observational nature of the study, these findings position ZAG as a potent dual-purpose biomarker. Future research should explore whether ZAG-targeted therapies could mitigate the debilitating process of muscle wasting and fat accumulation in the CKD population, potentially improving long-term survival and quality of life for dialysis patients.

Summary updated

Abstract

There were limited data on adipose and serum zinc alpha-2-glycoprotein (ZAG) expression and its association with body composition in patients with advanced chronic kidney disease (CKD). This study aimed to quantify adipose and serum ZAG expression and evaluate their association with body composition and its longitudinal change, together with mortality in incident dialysis patients. We performed a single-center prospective cohort study. Patients who were planned for peritoneal dialysis were recruited. ZAG levels were measured from serum sample, subcutaneous and pre-peritoneal fat tissue obtained during peritoneal dialysis catheter insertion. Body composition and functional state were evaluated by bioimpedance spectroscopy and Clinical Frailty Scale respectively at baseline and were repeated 1 year later. Primary outcome was 2-year survival. Secondary outcomes were longitudinal changes of body composition. At baseline, the average adipose and serum ZAG expression was 13.4 ± 130.0-fold and 74.7 ± 20.9 µg/ml respectively. Both adipose and serum ZAG expressions independently predicted adipose tissue mass (ATM) (p = 0.001, p = 0.008, respectively). At 1 year, ATM increased by 3.3 ± 7.4 kg (p < 0.001) while lean tissue mass (LTM) remained similar (p = 0.5). Adipose but not serum ZAG level predicted change in ATM (p = 0.007) and LTM (p = 0.01). Serum ZAG level predicted overall survival (p = 0.005) and risk of infection-related death (p = 0.045) after adjusting for confounders. In conclusion, adipose and serum ZAG levels negatively correlated with adiposity and predicted its longitudinal change of fat and lean tissue mass, whilst serum ZAG predicted survival independent of body mass in advanced CKD patient.
BibTeX
@inproceedings{chan2022adipose,
  author = {Gordon Chun‐Kau Chan and Win Hlaing Than and Bonnie Ching‐Ha Kwan and Ka‐Bik Lai and Ronald Chan and Jeremy Yuen‐Chun Teoh and Jack Kit‐Chung Ng and Kai‐Ming Chow and Winston Wing‐Shing Fung and Phyllis Mei‐Shan Cheng and Man-Ching Law and Chi‐Bon Leung and Philip Kam‐Tao Li and Cheuk‐Chun Szeto},
  title = {{Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-13149-6},
}
Figure